![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/biohaven-acquires-kleo-pharmaceuticals-and-licenses-platform-technology-from-yale-university-to-form-biohaven-labs-301202462.html
https://www.biospace.com/article/releases/biohaven-acquires-kleo-pharmaceuticals-and-licenses-platform-technology-from-yale-university-to-form-biohaven-labs/?s=79
https://www.globenewswire.com/fr/news-release/2020/12/07/2140728/0/en/Kleo-Pharmaceuticals-Presents-Preclinical-Data-on-KPMW135-a-Novel-CD3-x-CD20-Bispecific-Version-of-Rituximab-Showing-Increased-Anti-Tumor-Activity-Compared-to-Rituximab-at-The-62nd.html
https://www.biospace.com/article/releases/kleo-pharmaceuticals-to-present-at-bioscience-pipeline-and-innovation-in-connecticut-in-the-age-of-covid-conference/?s=73
https://www.globenewswire.com/news-release/2020/09/08/2090094/0/en/Kleo-Pharmaceuticals-Announces-Orphan-Drug-Designation-for-KP1237-in-Multiple-Myeloma.html#:~:text=NEW%20HAVEN%2C%20Conn.%2C%20Sept,the%20U.S.%20Food%20and%20Drug
https://www.globenewswire.com/news-release/2020/05/21/2036946/0/en/Kleo-Pharmaceuticals-and-Celularity-Enter-into-Research-Collaboration-to-Rapidly-Develop-Allogeneic-NK-Cell-Combination-Therapies-for-COVID-19-and-Multiple-Myeloma.html
https://www.globenewswire.com/news-release/2020/05/15/2034169/0/en/Kleo-Pharmaceuticals-to-Present-Preclinical-Data-Highlighting-the-Synergistic-Potential-of-Kleo-Asset-KP1237-and-Autologous-NK-Cells-in-the-Treatment-of-Multiple-Myeloma-at-the-202.html